Humane Genomics

Humane Genomics is developing oncolytic viruses with a modular synthetic biology platform to create targeted cancer therapies for oncologists and patients. Their key differentiation lies in overcoming the traditional tradeoff between therapeutic potency and selectivity in oncolytic viruses by employing a novel two-factor authentication mechanism for selectivity (cancer-specific receptors for honing, cancer-specific proteins for activation). They maximize efficiency by using a lytic RNA virus. A single systemic injection (IP) of their first product successfully treated Hep3B subcutaneous tumors in an immunodeficient mouse model.